S&P Futures
4,595.75 +20.00 (+0.44%) Dow Futures
34,746.00 +124.00 (+0.36%) Nasdaq Futures
16,055.25 +66.75 (+0.42%) Russell 2000 Futures
2,218.70 +13.50 (+0.61%) Crude Oil
68.80 +2.30 (+3.46%) Gold
1,768.50 +5.80 (+0.33%)
Protagonist Therapeutics, Inc. (PTGX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 30.93 |
| Open | 30.81 |
| Bid | 30.67 x 800 |
| Ask | 35.31 x 900 |
| Day's Range | 30.75 - 32.91 |
| 52 Week Range | 12.80 - 50.54 |
| Volume | |
| Avg. Volume | 2,034,896 |
| Market Cap | 1.56B |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.43 |
| Earnings Date | Nov 03, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.88 |
Fair Value
Related Research
- Protagonist Therapeutics, Inc.Weekly Stock ListVickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional ownership trends. Form 13-Fs are due 45 days after the end of calendar quarters, and have now come in from 2Q21. We like to review the 13Fs of the major activist investors, including Carl Icahn, Trian Fund Management, Jana Partners, and ValueAct Holdings, among others. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Here are some recent new purchases and key holdings of activist investors, according to Vickers.RatingFair ValueEconomic Moat11 days agoArgus Research
- PR Newswire
Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the upcoming JMP Securities Hematology and Oncology Summit taking place virtually on December 6, 2021.
- PR Newswire
Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23) pathway, under the Company's collaboration with Janssen Biotech, Inc. (Janssen). In addition to the previously announced Phase 2 clinical study of PN-235 in psoriasis, new Phase 2 clinical studies of PN-235 in inflammatory bowel diseases (IBD) are
- PR Newswire
Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH). HH is a genetic disorder arising from a deficiency or dysregulation of the natural hormone hepcidin, a condition which causes the body to absorb too much iron. The clinical data from the study were presented in an oral presentation at The Liver Meeting® of t
